Genetic Signatures Locks in 10-Year Danish Hospital Deal Worth 300,000+ Tests
Genetic Signatures has signed a 10-year supply agreement with Hvidovre Hospital in Denmark for gastrointestinal screening reagents and consumables, with an initial volume of 28,000 samples in year one and 3% estimated annual growth. The agreement, extendable by two 12-month periods, was secured through a competitive tender process and marks a strategic milestone for the company’s European expansion.
Genetic Signatures secures 10-year Danish hospital contract for gastrointestinal screening
Genetic Signatures has entered into a supply agreement with Hvidovre Hospital, one of Denmark’s leading public hospitals, for the provision of equipment, reagents, and consumables for gastrointestinal screening. The reagents and consumables agreement carries a 10-year term, with the option to extend for up to two additional 12-month periods. The equipment supply agreement has no fixed term, which is customary in supply agreements of this nature, but is generally expected to run eight years or longer.
The contract covers the testing of 28,000 samples in the first year, with an estimated 3% annual growth thereafter. Pricing details remain commercially sensitive and have not been publicly disclosed. Installation and validation will commence immediately, with commercial orders expected from September 2026.
The agreement was secured following a competitive tender process and will see Hvidovre Hospital adopt Genetic Signatures’ EasyScreen™ Pan-Enteric assay, which detects 24 gastrointestinal pathogens in a single, fully automated workflow.
When big ASX news breaks, our subscribers know first
What is pan-enteric testing and why does it matter?
The EasyScreen™ Pan-Enteric assay represents a fundamental shift in how laboratories approach gastrointestinal pathogen detection. Traditional methods require multiple tests: culturing techniques, enzyme-linked immunosorbent assays (ELISA), and several separate polymerase chain reaction (PCR) tests. Each method targets specific pathogen types, requiring laboratories to run numerous protocols across different platforms.
Genetic Signatures’ 3base® technology consolidates this complex multi-test approach into a streamlined workflow. The assay detects 24 gastrointestinal pathogens, including bacteria, viruses, and parasites, from a single patient sample in one automated run. This simplification reduces the need for multiple instruments, reagent inventories, and technical protocols.
For investors, this operational simplicity drives two key advantages. First, it lowers the barrier to adoption by reducing the technical and logistical burden on laboratories. Second, once embedded in laboratory operations, the platform creates switching costs. Laboratories that integrate the EasyScreen™ system into their workflows are less likely to revert to fragmented multi-platform testing.
UK validation demonstrates real-world hospital impact
The clinical and operational value of the pan-enteric approach has been validated in UK hospital environments following adoption of the EasyScreen™ Pan-Enteric assay. Key outcomes from these studies included:
- Reduction in ward closures following implementation
- Tripling of diagnostic yield and improved detection of clinically important pathogens
- Reduction of turnaround times and simplified laboratory workflows
- Reduction in staffing requirements and increased walk-away time
- Rapid results that directly informed admission decisions, bed management, targeted antibiotic use, and infection-control actions
- A marked decline in Clostridioides difficile infections
These outcomes demonstrate that the technology delivers measurable benefits across multiple dimensions of hospital operations. Faster turnaround times support clinical decision-making at the point of admission, while improved detection rates enable targeted treatment protocols that reduce unnecessary antibiotic use and hospital-acquired infection rates.
For investors, proven outcomes in comparable healthcare systems provide the evidence base that supports sales efforts across European markets. Hospitals increasingly require demonstrated value before procurement decisions, and the UK validation offers a reference framework that de-risks adoption for institutions evaluating the technology.
Health economics advantage
The benefits extend beyond the laboratory to system-wide health economics. By eliminating multi-platform complexity, the technology reduces operational risk and improves infection control. This translates to fewer unnecessary admissions, prevention of ward closures, and shorter patient stays.
These factors resonate with cost-conscious public health systems that are under pressure to deliver better outcomes with constrained budgets. The broader value proposition positions Genetic Signatures as offering more than a diagnostic tool—it provides a mechanism for improving hospital efficiency and patient flow.
Strategic milestone for European expansion
The Hvidovre Hospital contract represents a critical milestone for the company’s EMEA growth strategy. Denmark’s healthcare system is described as sophisticated and demanding, and success in this tender validates the clinical and operational case for the EasyScreen™ Pan-Enteric solution in international markets.
John Buckles, Director of EMEA Operations
“The Hvidovre Hospital tender is a critical milestone for Genetic Signatures’ EMEA growth strategy and further validates the clinical and operational case for our EasyScreen™ Pan-Enteric solution in international markets. Denmark has a sophisticated and demanding healthcare system, and we are proud that our technology meets the gastrointestinal diagnostic needs of Hvidovre Hospital.”
Public hospital contracts in demanding healthcare systems serve as reference sites that support sales cycles elsewhere in the region. Denmark’s rigorous procurement standards mean that success in this tender carries weight when approaching other European institutions.
CEO signals broader European momentum
The agreement also signals growing momentum for broader adoption across Europe and globally. CEO Maria Halasz framed the contract as evidence of real-world benefits that extend from laboratories to clinicians and patients.
Maria Halasz, CEO of Genetic Signatures
“This contract, combined with the outcomes we have seen in the UK and other markets, demonstrates that our pan-enteric approach delivers measurable, real-world benefits for laboratories, clinicians, and ultimately patients. We see this as a strong signal of growing momentum for broader adoption of our platform across Europe and globally.”
The language around “growing momentum” suggests an active pipeline of opportunities in the region. For investors, the key point is that this contract provides a template for future agreements in markets with similar healthcare system structures and procurement processes.
The next major ASX story will hit our subscribers first
Contract structure and commercial timeline
The commercial terms of the agreement are summarised below:
| Agreement Type | Term | Volume | Commercial Start |
|---|---|---|---|
| Reagents & Consumables | 10 years + two 12-month extensions | 28,000 samples year one, 3% annual growth | September 2026 |
| Equipment Supply | No fixed term (typically 8+ years) | Supporting infrastructure | Immediate installation |
The staggered commercial start—installation commencing immediately with commercial orders from September 2026—provides near-term catalyst visibility for revenue contribution in FY27. The 10-year term for reagents and consumables offers recurring revenue visibility over a decade-long horizon, with built-in volume growth of 3% annually. The two 12-month extension options provide potential for further term extension subject to performance and mutual agreement.
For investors, the structure offers predictable, long-term revenue underpinned by contract terms that reduce reliance on short-term sales cycles. The absence of disclosed pricing means the financial impact will be clarified in future reporting, but the volume trajectory provides a framework for modelling recurring revenue.
Want the Next Biotech Breakthrough in Your Inbox?
Join 20,000+ investors getting FREE breaking ASX healthcare news delivered within minutes of release, complete with in-depth analysis. Click the “Free Alerts” button at Big News Blast to start receiving real-time alerts the moment market-moving announcements break.